Hepatitis BBUVARD76_27NCT05390424
Screening for Hepatitis B, Hepatitis C and AIDS Viruses Using Dried Blood Spot
A study testing Blood collection using Dried Blood Spot in people with Hepatitis B and Hepatitis C, run by University Hospital, Rouen at 11 sites in France.
Trial summary
The aim of the study is to screen for hepatitis B, hepatitis C and AIDS viruses using a Dried Blood Spot in drug users Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hepatitis B, Hepatitis C, AIDS
- What is being tested?
- Blood collection using Dried Blood Spot
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 500 participants
- Where
- 11 sitesFrance
- Study dates
- 2 Dec 2022to Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Former or active intravenous and/or nasal drug user
- Person on opiate substitution therapy
Who cannot join
- Person with known active viral infection(s)
Trial locations and contacts
11 sites in 1 country. Contact the study team or a site near you to ask about taking part.
11 sites in 1 country
France11 sites, 11 recruiting
- Recruiting
Caarud Sud Manche
Avranches, 50300
Laure Perrot, Dr, laure.perrot@addictions-france.org
Laure Perrot, Dr
- Recruiting
Csapa Barentin
Barentin, 76360
Rémy Truchon, Dr, 02-35-92-82-58, remy.truchon@chbarentin.fr
Rémy Truchon, Dr
- Recruiting
Oeuvre Normande Des Meres
Dieppe, 76200
Christian Piart, Dr, Sophie.maillard@onm-dieppe.fr
Christian Piart, Dr
- Recruiting
Csapa Act
Elbeuf, 76500
Olga Leclercq, Dr, 0235780050, docteur.csapa@lapasserelle76.fr
Olga Leclercq, Dr
- Recruiting
Csapa Gisors
Gisors, 27140
Rémy Truchon, Dr, csapa@ch-gisors.fr
Rémy Truchon, Dr
- Recruiting
Csapa Nautilia
Le Havre, 76600
Quentin Berthon, Dr, qberthon@oppelia.fr
Quentin Berthon, Dr
- Recruiting
Csapa Pont-Audemer
Pont-Audemer, 27504
Marie-Claude Flavigny, Dr, csapa@ch-pont-audemer.fr
Marie-Claude Flavigny, Dr
- Recruiting
Aides Region Normandie
Rouen, 76000
Julien Bord, Dr, bordjulien76@gmail.com
Julien Bord, Dr
- Recruiting
Csapa-Caarud La Boussole
Rouen, 76000
Véronique Michel, Dr, 02.35.89.12.02., rouillech@wanadoo.fr
Véronique Michel, Dr
- Recruiting
Chu Rouen
Rouen, 76031
Ghassan Riachi, Dr, 0232888990, Ghassan.riachi@chu-rouen.fr
Ghassan Riachi, Dr
- Recruiting
Csapa Caux Et Bray
Yvetot, 76190
Alexandre Hai, Dr, csapa@chbarentin.fr
Alexandre Hai, Dr
About this study
The aim of the study is to screen for hepatitis B, hepatitis C and AIDS viruses using a Dried Blood Spot in drug users
- Conditions
- Hepatitis B, Hepatitis C, AIDS
- Being tested
- Blood collection using Dried Blood Spot
- Keywords
- Dried Blood Spot
- Medical subject headings
- Hepatitis B, Hepatitis C, Acquired Immunodeficiency Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood collection using Dried Blood SpotDiagnostic test
Drug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection
| Study group | Role | What they receive |
|---|---|---|
| Drug user | Experimental | Drug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection Receives: Diagnostic Test: Blood collection using Dried Blood Spot |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of person with an active hepatitis C infection
Measured: Day 1
Number of person with an active hepatitis B infection
Measured: Day 1
Number of person with an active AIDS infection
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 May 2022
- Study start2 Dec 2022
- Primary completionJan 2027 (estimated)
- Study completionJan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hepatitis BStudies of the same condition, open and under way.
- More trials run by University Hospital, RouenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Rouen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Ghassan RIACHI, MD, Principal investigator, University Hospital, Rouen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05390424
- Sponsor's protocol ID
- 2021/0098/HP
- Acronym
- BUVARD76_27
- Status last verified
- Feb 2026
- First submitted
- 20 May 2022
- Last updated
- 17 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Screening for Hepatitis B, Hepatitis C and AIDS Viruses Using Dried Blood Spot
- ClinicalTrials.gov ID
- NCT05390424
- Acronym / sponsor ID
- BUVARD76_27 / 2021/0098/HP
- Conditions
- Hepatitis B, Hepatitis C, AIDS
- Keywords
- Dried Blood Spot
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- University Hospital, RouenUniversity, hospital or other
- Study start
- 2 Dec 2022 (actual)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Jan 2027 (estimated)
- First posted
- 25 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to screen for hepatitis B, hepatitis C and AIDS viruses using a Dried Blood Spot in drug users
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Drug user | Experimental | Diagnostic Test: Blood collection using Dried Blood SpotDrug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Former or active intravenous and/or nasal drug user
- Person on opiate substitution therapy
Key exclusion criteria (1 listed)
- Person with known active viral infection(s)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood collection using Dried Blood SpotDrug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection | Diagnostic test | Drug user |
Primary outcome
Number of person with an active hepatitis C infection
Time frame: Day 1
Number of person with an active hepatitis B infection
Time frame: Day 1
Number of person with an active AIDS infection
Time frame: Day 1
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Hepatitis B
Active, not recruitingPhase 4
Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines
Chronic Hepatitis b
Active, not recruitingPhase 4
Effectiveness of Antiviral Treatment in Cirrhotic Patients With Low-level Hepatitis B Virus DNA Levels
Hepatitis B, Chronic
Active, not recruitingPhase 1/2
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
Recruiting
A Study to Evaluate the Performance, and Usability of TruPlex HIV/HepB/Syphilis Rapid Test
HIV1 Infection, HIV 2 Infection
RecruitingObservational study
Evaluation of Patients With Liver Disease
Hepatitis D, Hepatitis C
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ghassan RIACHI, MD principal investigator
University Hospital, Rouen
11 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Blood collection using Dried Blood Spot in people with Hepatitis B and Hepatitis C, run by University Hospital, Rouen at 11 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 11 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ghassan RIACHI, MD (+3323288 ext. 8265, ghassan.riachi@chu-rouen.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of person with an active hepatitis C infection (time frame: Day 1). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2026.